How to access Augtyro for ROS1-positive non-small-cell lung cancer and NTRK-positive solid tumours from Oman: 2026 pathway via Oman oncology and regional referral

Name: How to access Augtyro for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumours from Oman: 2026 pathway via Oman oncology and regional referral | Reserve Meds
Published: 2026-05-20

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

Oman's adult medical oncology services run out of Sultan Qaboos University Hospital (SQUH) (KHUH), Royal Hospital Muscat, and Muscat Private Hospital, with established referral pathways to KFSHRC Riyadh, NCCCR Doha, and the UAE oncology centres for cases requiring deeper subspecialty infrastructure. Paediatric NTRK cases age 12 and older typically refer cross-border to KFSHRC paediatric oncology or to Sidra Medicine via the MoH treatment-abroad pathway. Augtyro (repotrectinib) is a Bristol Myers Squibb next-generation tyrosine kinase inhibitor covering ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults and NTRK gene fusion-positive solid tumours in adults and paediatric patients age 12 years and older. The FDA approved ROS1 in November 2023 and expanded to NTRK fusions in June 2024. Oman supply route in 2026 most commonly runs through the named-patient programme (NPP) pathway via the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC).

This page explains how the pathway works in 2026 for a Oman-resident patient: who qualifies, where the diagnostic and molecular workup happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in OMR, what to monitor on therapy, and how the multi-year treatment course settles into an Omani family's life.

Why Augtyro, and why now

Augtyro is repotrectinib (TPX-0005), discovered at Turning Point Therapeutics, acquired by Bristol Myers Squibb in August 2022. FDA approved November 2023 for ROS1-positive locally advanced or metastatic NSCLC in adults (TRIDENT-1, ORR 79 percent TKI-naive, intracranial ORR 89 percent). Expanded June 2024 to NTRK gene fusion-positive solid tumours in adults and paediatric patients age 12 and older (TRIDENT-1 NTRK cohort, ORR 58 percent TKI-naive).

For an Omani patient with confirmed ROS1-positive NSCLC or NTRK-positive solid tumour, Augtyro is the named-patient route for first-line or post-first-generation-TKI treatment under most institutional protocols followed by KHUH, Royal Hospital Muscat, and Muscat Private Hospital. The eligibility gatekeeper is biomarker confirmation.

What Augtyro is, in plain language

Augtyro is an oral capsule. 160 mg once daily for 14 days (lead-in), then 160 mg twice daily (maintenance), with food. Room temperature storage. No infusion, no inpatient stay, no certified-centre requirement.

The 14-day lead-in is about managing initial dizziness. Driver support during the first two weeks is part of the practical handoff.

For metastatic disease, treatment continues until disease progression or intolerable toxicity. Dose reductions are pre-specified (160 mg twice daily, then 120 mg twice daily, then 80 mg twice daily) and the protocol allows dose interruptions for management of toxicity.

Biomarker prerequisites

Augtyro eligibility rests on a validated molecular result, not on imaging or clinical pattern. For NSCLC, ROS1 rearrangement is confirmed by fluorescence in situ hybridisation (FISH), reverse transcription polymerase chain reaction (RT-PCR), or RNA-based next-generation sequencing on the tumour tissue or, where validated, on liquid biopsy. For solid tumours of other histologies, NTRK1, NTRK2, or NTRK3 gene fusion is confirmed by RNA-based NGS or by validated FISH/immunohistochemistry follow-up. SQUH and the Royal Hospital cytogenetics and molecular pathology services run validated NGS panels; cases lacking a local molecular result typically route to KFSHRC Riyadh, NCCCR Doha, or the major UAE academic oncology centres for tissue review and panel testing.

The DGPADC named-patient pathway in Oman

The Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) operates the personal-use named-patient import authorisation under Royal Decree 35/2015 and subsequent pharmaceutical regulations. The treating oncologist at SQUH, the Royal Hospital Muscat, the National Oncology Centre, or a licensed private oncology service files the prescription and clinical justification documenting the diagnosis, the molecular result, prior therapies, and the rationale

Regulatory status of Augtyro (repotrectinib) in Oman, 2026

Augtyro (repotrectinib) is approved by the US Food and Drug Administration for the labelled indication of ROS1-positive locally advanced or metastatic NSCLC, and NTRK-positive solid tumours (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Oman-based patient, the access pathway runs through the Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control framework. The official regulator portal is at www.moh.gov.om; the locally registered medicines list is at www.moh.gov.om/en/services/medicine-licensing.

Where Augtyro (repotrectinib) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Augtyro (repotrectinib) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.

Tertiary centers and clinical coordination in Oman

The Oman tertiary referral network for a Augtyro (repotrectinib) case is concentrated at Sultan Qaboos University Hospital (SQUH), The Royal Hospital Muscat, Sultan Qaboos Comprehensive Cancer Care and Research Centre, and Khoula Hospital. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For next-generation ROS1/NTRK tyrosine kinase inhibitor therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.

For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Oman once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Oman; the Oman tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.

Oman pricing reference and payer posture, 2026

Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for OMR conversion is 1 USD = 0.385 OMR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Augtyro (repotrectinib) reflects the US wholesale acquisition cost published by the manufacturer (Bristol Myers Squibb) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.

Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.

Payer posture in Oman is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is MoH public-sector coverage for Omani nationals; commercial insurance via DhofarInsurance, AXA Gulf, NLGI Oman; the portal is at www.moh.gov.om. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.

Access barriers and how Reserve Meds clears them

The five access barriers we see most often for a Augtyro (repotrectinib) case in Oman are: (1) Regulatory documentation complexity. The Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Augtyro (repotrectinib) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.

(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Oman physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.

Drug-specific clinical context for Augtyro (repotrectinib): the labelled indication is ROS1-positive locally advanced or metastatic NSCLC, and NTRK-positive solid tumours. The next-generation ROS1/NTRK tyrosine kinase inhibitor mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is National Comprehensive Cancer Network (NCCN) non-small cell lung cancer guidelines at www.nccn.org/guidelines/category_1. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.

Recent regulatory and access news for Augtyro (repotrectinib) in Oman, 2026

The Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control portal at www.moh.gov.om and the locally registered medicines list at www.moh.gov.om/en/services/medicine-licensing are the authoritative source for the current Oman listing status of Augtyro (repotrectinib); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Augtyro (repotrectinib) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Augtyro (repotrectinib) remains ROS1-positive locally advanced or metastatic NSCLC, and NTRK-positive solid tumours (see the current FDA approval record at accessdata.fda.gov). Bristol Myers Squibb continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The National Comprehensive Cancer Network (NCCN) non-small cell lung cancer guidelines guidance at www.nccn.org/guidelines/category_1 remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.